Dementia Discovery Fund’s investments: Data Byte

Since its launch by SV Health Investors in 2015 to fund new thinking in Alzheimer’s and other neurological diseases, Dementia Discovery Fund (DDF) has funded one to four companies per year exploring new hypotheses, such as neuroinflammatory pathways, and new technologies, from RNA modulation to digital biomarkers.

At the halfway point, this year already is at the high end of that range, with the fund so far investing in four companies: immunology plays Therini Bio Inc. and Alchemab Therapeutics Ltd., digital biomarker company Cumulus Neuroscience, and most recently, Transine Therapeutics Ltd., which is developing long non-coding RNAs known as SINEUPs...